Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from…

Read More

A.O. Smith stock hits 52-week low at $61.99

A.O. Smith Corp’s stock recently reached a 52-week low, touching $61.99, with shares currently trading at $62.08—just above that floor. This milestone reflects a challenging period for the company, as the stock has experienced a 1-year decline of 4.7%. Yet InvestingPro data suggests the stock may be undervalued, with a Fair Value indicating potential upside,…

Read More